Clinical Features of Vitiligo and Social Impact on Quality of Life

Overview

Journal Dermatol Pract Concept

Specialty Dermatology

Date 2024 Jan 19

PMID 38241394

Authors

Julien Seneschal

Affiliations

Soon will be listed here.

Abstract

Vitiligo is the most common cause of depigmentation and its estimated worldwide prevalence ranges from 0.5% to 2%. The disease is characterized by the development of white macules resulting from a loss of epidermal melanocytes. The term vitiligo (nonsegmental) is now a consensus umbrella term for all forms of generalized vitiligo. Two other subsets of vitiligo are segmental vitiligo and unclassified/undetermined vitiligo, which corresponds to focal disease and rare variants. A series of hypopigmented disorders may masquerade as vitiligo, and some of them need to be ruled out by specific procedures including a skin biopsy. The skin plays an important role in our interaction with the world and any change in the skin colour can have important psychological consequences. In this line, vitiligo has a major impact on quality of life.In this review, we will detail the most recent data on the clinical features of vitiligo and its impact on quality of life.

Citing Articles

Vitiligo Exchange: An Expert Panel Discussion of Two Clinical Cases.

Del Rosso J, Hamzavi I, Grimes P J Clin Aesthet Dermatol. 2025; 17(12 Suppl 3):S9-S18.

PMID: 39830989 PMC: 11740887.

Assessment of Efficacy on the Treatment of Localized Vitiligo With a Combination of 308 nm Excimer Light and 2940 Erbium Laser: A Retrospective Study.

Xie Y, Shi W, Yin W, Mei X J Cosmet Dermatol. 2024; 24(2):e16715.

PMID: 39645646 PMC: 11845925. DOI: 10.1111/jocd.16715.

References

Talsania N, Lamb B, Bewley A . Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol. 2009; 35(7):736-9. DOI: 10.1111/j.1365-2230.2009.03765.x. View

Porter J, Beuf A, Nordlund J, LERNER A . Psychological reaction to chronic skin disorders: a study of patients with vitiligo. Gen Hosp Psychiatry. 1979; 1(1):73-7. DOI: 10.1016/0163-8343(79)90081-1. View

Nogueira L, Zancanaro P, Azambuja R . [Vitiligo and emotions]. An Bras Dermatol. 2009; 84(1):41-5. DOI: 10.1590/s0365-05962009000100006. View

Ezzedine K, Diallo A, Leaute-Labreze C, Seneschal J, Prey S, Ballanger F . Halo naevi and leukotrichia are strong predictors of the passage to mixed vitiligo in a subgroup of segmental vitiligo. Br J Dermatol. 2011; 166(3):539-44. DOI: 10.1111/j.1365-2133.2011.10709.x. View

Salzes C, Abadie S, Seneschal J, Whitton M, Meurant J, Jouary T . The Vitiligo Impact Patient Scale (VIPs): Development and Validation of a Vitiligo Burden Assessment Tool. J Invest Dermatol. 2016; 136(1):52-8. DOI: 10.1038/JID.2015.398. View

Linthorst Homan M, de Korte J, Grootenhuis M, Bos J, Sprangers M, van der Veen J . Impact of childhood vitiligo on adult life. Br J Dermatol. 2008; 159(4):915-20. DOI: 10.1111/j.1365-2133.2008.08788.x. View

Schmid-Ott G, Kunsebeck H, Jecht E, Shimshoni R, Lazaroff I, Schallmayer S . Stigmatization experience, coping and sense of coherence in vitiligo patients. J Eur Acad Dermatol Venereol. 2007; 21(4):456-61. DOI: 10.1111/j.1468-3083.2006.01897.x. View

Picardo M, DellAnna M, Ezzedine K, Hamzavi I, Harris J, Parsad D . Vitiligo. Nat Rev Dis Primers. 2016; 1:15011. DOI: 10.1038/nrdp.2015.11. View

Oh J, Lee R, Lee H, Lee S, Ju H, Park J . Classification of facial and truncal segmental vitiligo and its clinical courses including recurrence rate and patterns: a retrospective review of 956 patients. Br J Dermatol. 2020; 184(4):750-753. DOI: 10.1111/bjd.19661. View

10.

Ezzedine K, Le Thuaut A, Jouary T, Ballanger F, Taieb A, Bastuji-Garin S . Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res. 2013; 27(1):134-9. DOI: 10.1111/pcmr.12186. View

11.

Manzoni A, Weber M, Nagatomi A, Pereira R, Townsend R, Cestari T . Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol. 2014; 88(6):894-9. PMC: 3900338. DOI: 10.1590/abd1806-4841.20131915. View

12.

Taieb A, Seneschal J, Mazereeuw-Hautier J . Special Considerations in Children with Vitiligo. Dermatol Clin. 2017; 35(2):229-233. DOI: 10.1016/j.det.2016.11.011. View

13.

Sosa J, Currimbhoy S, Ukoha U, Sirignano S, OLeary R, Vandergriff T . Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo. J Am Acad Dermatol. 2015; 73(2):272-5. DOI: 10.1016/j.jaad.2015.05.014. View

14.

van Geel N, Grine L, De Wispelaere P, Mertens D, Prinsen C, Speeckaert R . Clinical visible signs of disease activity in vitiligo: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2019; 33(9):1667-1675. DOI: 10.1111/jdv.15604. View

15.

Parsad D, Dogra S, Kanwar A . Quality of life in patients with vitiligo. Health Qual Life Outcomes. 2003; 1:58. PMC: 269995. DOI: 10.1186/1477-7525-1-58. View

16.

Silverberg N . Recent advances in childhood vitiligo. Clin Dermatol. 2014; 32(4):524-30. DOI: 10.1016/j.clindermatol.2014.02.006. View

17.

Picardo M, Huggins R, Jones H, Marino R, Ogunsola M, Seneschal J . The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J Eur Acad Dermatol Venereol. 2022; 36(9):1507-1523. PMC: 9790455. DOI: 10.1111/jdv.18129. View

18.

van Geel N, Speeckaert R, Taieb A, Picardo M, Bohm M, Gawkrodger D . Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res. 2011; 24(3):564-73. DOI: 10.1111/j.1755-148X.2011.00838.x. View

19.

Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo F, Sturm D . Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol. 2021; 22(6):757-774. PMC: 8566637. DOI: 10.1007/s40257-021-00631-6. View

20.

Kruger C, Schallreuter K . Cumulative life course impairment in vitiligo. Curr Probl Dermatol. 2013; 44:102-17. DOI: 10.1159/000350010. View